TIAA CREF Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

TIAA CREF Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$892K	Hold	174,921	–	–	﹤0.01%	2378
2018 Q4	$336K	Sell	174,921 -78,895	-31%	-$226K	﹤0.01%	2734
2018 Q3	$959K	Sell	253,816 -159,864	-39%	-$501K	﹤0.01%	2437
2018 Q2	$1.29M	Buy	413,680 +58,353	+16%	+$177K	﹤0.01%	2390
2018 Q1	$849K	Buy	355,327 +171,840	+94%	+$571K	﹤0.01%	2515
2017 Q4	$717K	Sell	183,487 -7,786	-4%	-$25.7K	﹤0.01%	2626
2017 Q3	$482K	Hold	191,273	–	–	﹤0.01%	2842
2017 Q2	$528K	Buy	+191,273	New	+$399K	﹤0.01%	2841
2016 Q2	–	Sell	-308,113	Closed	-$360K	–	3157
2016 Q1	$360K	Buy	308,113 +51,252	+20%	+$79.5K	﹤0.01%	2875
2015 Q4	$629K	Hold	256,861	–	–	﹤0.01%	2813
2015 Q3	$771K	Buy	256,861 +104,663	+69%	+$452K	﹤0.01%	2722
2015 Q2	$629K	Buy	+152,198	New	+$607K	﹤0.01%	2896

Other funds holding CPRX

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

TIAA CREF Investment Management's CPRX Position: Q1 2019 in Review

TIAA CREF Investment Management held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2019 at 174,921 shares worth $892K. The position accounts for ﹤0.01% of the portfolio, ranked #2378.

TIAA CREF Investment Management first reported a position in CPRX in Q2 2015 and has held it in 12 quarters since. The position peaked at $1.29M in Q2 2018. 88 funds tracked by Wall St. Rank hold CPRX as of Q1 2019.

TIAA CREF Investment Management held 174,921 shares of Catalyst Pharmaceutical worth $892K as of Q1 2019.
TIAA CREF Investment Management left its Catalyst Pharmaceutical share count unchanged in Q1 2019.
Catalyst Pharmaceutical made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2378 holding.
TIAA CREF Investment Management first reported a position in Catalyst Pharmaceutical in Q2 2015 and has held it in 12 quarters since.
TIAA CREF Investment Management's Catalyst Pharmaceutical position peaked at $1.29M in Q2 2018.
88 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.